Citrullinated peptides as drug candidates for rheumatoid arthritis

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• Rheumatoid arthritis (RA) is characterized by immune system breakdown, targeting citrullinated proteins, causing chronic inflammation and joint damage.
• Current RA treatments struggle to achieve long-term remission, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review the potential of using citrullinated proteins/peptides to restore immune tolerance in RA.
• To explore the role of anti-citrullinated protein antibodies (ACPAs) and targeted antigens in disease pathology.
• To evaluate emerging tolerance-based strategies for durable RA treatment.

Main Methods:

• Review of existing literature on immune tolerance induction in RA.
• Analysis of mechanisms involving T and B cell modulation by citrullinated antigens.
• Examination of strategies promoting regulatory T (Treg) cell expansion and altering pathogenic B cell subsets.

Main Results:

• Citrullinated proteins/peptides show promise for reestablishing immune tolerance in RA.
• Modulating specific citrullinated antigens can influence immune responses.
• Altering T and B cell function is therapeutically relevant for immune regulation in RA.

Conclusions:

• Restoring immune tolerance is a promising strategy to halt RA progression and achieve sustained remission.
• Tolerance-based approaches, including Treg expansion and B cell modulation, offer potential for effective and durable RA treatment.
• Re-educating the immune system to shift away from autoimmunity is key for long-term RA remission.